SYRE

Spyre Therapeutics, Inc · NASDAQ

Sector Health Technology
Industry Biotechnology
Website yre.com
Employees(FY) 69
ISIN US00773J2024

Performance

-23.23%

-16.06%

-1.26%

-27.25%

+27.79%

YTD

+161.9%

Profile

Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Advanced Technical Analysis

Technical Analysis of SYRE 2024-11-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 46 suggesting a neutral stance, and a Technical Score of 28 reinforcing the bearish outlook. This combination points to a challenging environment for the stock, with potential for further declin...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SYRE

Stock Rank

Recent News & Updates

2024-11-18 21:18
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock(PR Newswire)
2024-11-18 16:14
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants(PR Newswire)
2024-11-18 08:18
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock(Prnewswire)
2024-11-18 03:14
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants(Prnewswire)
2024-11-12 07:30
Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential fo(PR Newswire)
2024-11-11 18:30
Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-47 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for (Prnewswire)
2024-11-11 16:05
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024(PR Newswire)
2024-11-11 03:05
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-47 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024(Prnewswire)
2024-11-07 16:05
Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update(PR Newswire)
2024-11-07 03:05
Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update(Prnewswire)
2024-11-01 16:44
Spyre Therapeutics Announces Grants of Inducement Awards(PR Newswire)
2024-11-01 04:44
Spyre Therapeutics Announces Grants of Inducement Awards(Prnewswire)
2024-10-30 16:05
Spyre Therapeutics to Participate in Upcoming November Investor Conferences(PR Newswire)
2024-10-30 04:05
Spyre Therapeutics to Participate in Upcoming November Investor Conferences(Prnewswire)
2024-10-14 08:00
Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations(PR Newswire)
2024-10-13 20:00
Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations(Prnewswire)
2024-10-04 17:00
Spyre Therapeutics Announces Grants of Inducement Awards(PR Newswire)
2024-10-04 05:00
Spyre Therapeutics Announces Grants of Inducement Awards(Prnewswire)
2024-10-01 08:00
Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer(PR Newswire)
2024-09-30 20:00
Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer(Prnewswire)
2024-09-10 16:47
Spyre Therapeutics to Participate in Upcoming Investor Conference(PR Newswire)
2024-09-10 04:47
Spyre Therapeutics to Participate in Upcoming Investor Conference(Prnewswire)
2024-08-07 16:05
Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update(PR Newswire)
2024-08-07 11:53
SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024(Investorplace)
2024-08-07 04:05
Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update(Prnewswire)
2024-07-18 08:00
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors(GlobeNewswire)
2024-07-17 20:00
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors(Globenewswire)
2024-06-18 07:30
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease(PR Newswire)
2024-06-17 19:30
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-47 Antibody, for the Treatment of Inflammatory Bowel Disease(Prnewswire)
2024-06-03 17:23
Spyre Therapeutics Announces Grants of Inducement Awards(PR Newswire)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.